MassDevice Article: Device-Agnostic Data Collection And The Future Of Digital Health

MassDevice editor, Sean Whooley, recently wrote an article about how PhysIQ’s partnership with J&J’s Janssen Pharmaceuticals will advance digital therapeutics in a story published May 12, 2021: How PhysIQ is advancing digital therapeutics through its partnership with Janssen.

Product Creation Studio CTO, Scott Thielman, weighed in on the implications of this partnership to the future digital health landscape.

“Scott Thielman, the CTO of product development consultancy company Product Creation Studio, told?MassDevice?that players in the space like Janssen are looking for platforms like what PhysIQ offers: those that are “far abstracted beyond the concepts of cloud, edge processing and wireless links” upon which they can build.

“Collection and management of clinical study data is an incredibly important operation that happens to lie just outside of the development activities that most drug companies really want to focus their internal resources on,” Thielman said. “The data itself is a precious, high-value asset so it makes sense for players like Janssen to choose a best-in-class partner platform. There will continue to be a role for PhysIQ and similar companies that bring insights to their customers rather than just data aggregation.”

Article excerpt:

Over the course of the last year and some change, the impact of digital health and the need for it has increased by an immeasurable amount.

Virtual care became the norm after the COVID-19 pandemic hit, and, although a return to something resembling “normal” could be on the horizon, those at artificial intelligence–based technology developer PhysIQ see that the landscape has been reshaped since early 2020.

“Digital medicine has been evolving but a lot of what’s been done has been done in an exploratory capacity,” PhysIQ CCO Chris Economos told?MassDevice. “COVID-19 has definitely changed that.”

In the throes of the pandemic in September,?PhysIQ was among a number of companies to receive government contracts to aid in the battle against COVID-19.